[go: up one dir, main page]

SI0933372T1 - Sulfonamidni derivati kot predzdravila inhibitorjev aspartil proteaze - Google Patents

Sulfonamidni derivati kot predzdravila inhibitorjev aspartil proteaze

Info

Publication number
SI0933372T1
SI0933372T1 SI9830903T SI9830903T SI0933372T1 SI 0933372 T1 SI0933372 T1 SI 0933372T1 SI 9830903 T SI9830903 T SI 9830903T SI 9830903 T SI9830903 T SI 9830903T SI 0933372 T1 SI0933372 T1 SI 0933372T1
Authority
SI
Slovenia
Prior art keywords
prodrugs
protease inhibitors
aspartyl protease
sulphonamide derivatives
sulphonamide
Prior art date
Application number
SI9830903T
Other languages
English (en)
Inventor
Robert D Tung
Michael R Hale
Christopher T Baker
Eric Steven Furfine
Istvan Kaldor
Wieslaw Mieczyslaw Kazmierski
Andrew Spaltenstein
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25544691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI0933372(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of SI0933372T1 publication Critical patent/SI0933372T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
SI9830903T 1997-12-24 1998-03-10 Sulfonamidni derivati kot predzdravila inhibitorjev aspartil proteaze SI0933372T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/998,050 US6436989B1 (en) 1997-12-24 1997-12-24 Prodrugs of aspartyl protease inhibitors
EP98104292A EP0933372B1 (en) 1997-12-24 1998-03-10 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors

Publications (1)

Publication Number Publication Date
SI0933372T1 true SI0933372T1 (sl) 2008-06-30

Family

ID=25544691

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9830903T SI0933372T1 (sl) 1997-12-24 1998-03-10 Sulfonamidni derivati kot predzdravila inhibitorjev aspartil proteaze

Country Status (42)

Country Link
US (5) US6436989B1 (sl)
EP (2) EP0933372B1 (sl)
JP (3) JP3736964B2 (sl)
KR (1) KR100520737B1 (sl)
CN (2) CN101565412A (sl)
AP (1) AP1172A (sl)
AR (1) AR017965A1 (sl)
AT (1) ATE382042T1 (sl)
AU (1) AU755087B2 (sl)
BG (1) BG64869B1 (sl)
BR (1) BR9814480A (sl)
CA (1) CA2231700C (sl)
CO (1) CO4990992A1 (sl)
CZ (1) CZ301653B6 (sl)
DE (2) DE69838903T2 (sl)
DK (1) DK0933372T3 (sl)
EA (1) EA003509B1 (sl)
EE (1) EE04466B1 (sl)
ES (1) ES2299193T3 (sl)
FR (1) FR08C0015I2 (sl)
HU (2) HU229596B1 (sl)
ID (1) ID24962A (sl)
IL (2) IL136941A0 (sl)
IS (1) IS2817B (sl)
LU (1) LU91426I2 (sl)
ME (1) MEP82008A (sl)
MY (1) MY131525A (sl)
NL (1) NL300339I2 (sl)
NO (2) NO326265B1 (sl)
NZ (1) NZ505776A (sl)
OA (1) OA11468A (sl)
PE (1) PE20000048A1 (sl)
PL (1) PL202845B1 (sl)
PT (1) PT933372E (sl)
RS (1) RS52483B (sl)
SI (1) SI0933372T1 (sl)
SK (1) SK287123B6 (sl)
TR (1) TR200002615T2 (sl)
TW (1) TW486474B (sl)
UA (1) UA72733C2 (sl)
WO (1) WO1999033815A1 (sl)
ZA (1) ZA9811830B (sl)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) * 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
IL139787A0 (en) 1998-06-02 2002-02-10 Osi Pharm Inc PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
WO2000018384A2 (en) * 1998-09-28 2000-04-06 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylic acid isopropyl ester and amprenavir
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
AP1504A (en) 2001-02-14 2005-12-10 Tibotec Pharm Ltd Broadspectrum 2- (substituted-amino) -benzothiazole sulfonamide HIV protease inhibitors
KR100872029B1 (ko) 2001-04-09 2008-12-05 티보텍 파마슈티칼즈 리미티드 광범위 2-(치환된-아미노)-벤즈옥사졸 설폰아미드 ｈｉｖ프로테아제 저해제
CA2444895C (en) 2001-05-11 2011-02-15 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-amino-benzoxazole sulfonamide hiv protease inhibitors
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
EP2050751A1 (en) 2001-11-30 2009-04-22 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
CN1620294A (zh) 2001-12-20 2005-05-25 Osi药物公司 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
IL162574A0 (en) 2001-12-21 2005-11-20 Tibotec Pharm Ltd Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
WO2003090691A2 (en) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Method and compositions for identifying anti-hiv therapeutic compounds
TWI356700B (en) 2002-05-17 2012-01-21 Tibotec Pharm Ltd Broadspectrum substituted benzisoxazole sulfonamid
PL375307A1 (en) 2002-08-14 2005-11-28 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2425031A1 (en) * 2003-04-01 2004-10-01 Smithkline Beecham Corporation Pharmaceutical compositions
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
CA2522845A1 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
EA200600221A1 (ru) 2003-07-09 2006-06-30 Пэрэтек Фамэсьютикэлс, Инк. Замещённые соединения тетрациклина (варианты), фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
CA2531732C (en) * 2003-07-09 2012-04-10 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
US20050119163A1 (en) * 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
US8193227B2 (en) 2003-12-11 2012-06-05 Abbott Laboratories HIV protease inhibiting compounds
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
US7834043B2 (en) * 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
EP2153832B1 (en) * 2003-12-15 2016-03-09 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
AU2004298448B2 (en) 2003-12-18 2010-09-09 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
NZ547907A (en) 2003-12-22 2010-07-30 Gilead Sciences Inc 4'-Substituted carbovir-and abacavir-derivatives as well as related compounds with HIV and HCV antiviral activity
MXPA06015108A (es) * 2004-07-06 2007-03-26 Abbott Lab Profarmacos inhibidores de la proteasa del virus de la inmunodeficiencia humana.
NZ553405A (en) 2004-07-27 2010-03-26 Gilead Sciences Inc Nucleoside phosphonate conjugates as anti-HIV agents
EP1773763B1 (en) * 2004-08-02 2008-12-17 Ambrilia Biopharma Inc. Lysine based compounds
US7388008B2 (en) * 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
RU2379312C2 (ru) * 2004-08-02 2010-01-20 Амбрилиа Байофарма Инк. Соединения на основе лизина, фармацевтическая композиция, содержащая эти соединения, применение указанных соединений для лечения или профилактики вич инфекции
WO2006024490A2 (en) 2004-08-30 2006-03-09 Interstitial Therapeutics Methods and compositions for the treatment of cell proliferation
BRPI0516915A (pt) 2004-12-01 2008-03-11 Devgen Nv derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
DK1941798T3 (da) 2004-12-17 2012-08-27 Devgen Nv Nematicide præparater
EP1856135B1 (en) * 2005-01-19 2009-12-09 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
EP1855672A4 (en) * 2005-03-11 2011-11-30 Glaxosmithkline Llc HIV PROTEASE INHIBITORS
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
EP1877091B1 (en) * 2005-04-27 2015-03-25 TaiMed Biologics, Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
WO2007045496A1 (en) 2005-10-21 2007-04-26 Universiteit Antwerpen Novel urokinase inhibitors
TWI432438B (zh) 2005-11-28 2014-04-01 Tibotec Pharm Ltd 作為ｈｉｖ蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物及衍生物
TWI385173B (zh) 2005-11-28 2013-02-11 Tibotec Pharm Ltd 作為ｈｉｖ蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
CA2632095A1 (en) * 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
ZA200805011B (en) 2005-12-27 2009-11-25 Otsuka Pharma Co Ltd Water-soluble benzoazepine compound and its pharmaceutical composition
CN101490060B (zh) 2006-07-13 2012-04-11 詹森药业有限公司 Mtki喹唑啉衍生物
EP3056509A1 (en) 2006-09-08 2016-08-17 Piramal Imaging SA Bombesin analogues for use in diagnosis
US8410300B2 (en) * 2006-09-21 2013-04-02 Taimed Biologics, Inc. Protease inhibitors
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
EP2131865B1 (en) 2007-03-12 2014-12-17 Nektar Therapeutics Oligomer-protease inhibitor conjugates
US8318731B2 (en) 2007-07-27 2012-11-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
EP2053033A1 (en) 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
JP5480824B2 (ja) 2008-03-10 2014-04-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐｌｋキナーゼ阻害剤としての４−アリール−２−アニリノ−ピリミジン
EP2262538B1 (en) * 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-amino acid conjugate
EP2116236A1 (en) 2008-04-21 2009-11-11 Université de Mons-Hainaut Bisbenzamidine derivatives for use as antioxidant
KR101642527B1 (ko) 2008-07-08 2016-07-25 길리애드 사이언시즈, 인코포레이티드 Ｈｉｖ 억제제 화합물의 염
TWI557117B (zh) 2008-12-09 2016-11-11 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
WO2010134045A1 (en) * 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
CA2774483C (en) 2009-09-16 2014-11-18 Ranbaxy Laboratories Limited Process for the preparation of fosamprenavir calcium
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
EP2501431B1 (en) 2009-11-19 2020-01-08 Wellinq Medical B.V. Narrow profile composition-releasing expandable medical balloon catheter
EP2507250A1 (en) 2010-01-07 2012-10-10 Pliva Hrvastka D.O.O. Solid state forms of fosamprenavir calcium salt and process for preparation thereof
EP2932970B1 (en) 2010-01-27 2018-03-21 VIIV Healthcare Company Antiviral therapy
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (en) 2010-03-19 2011-09-22 Lupin Limited Ammonium, calcium and tris salts of fosamprenavir
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
WO2011141515A1 (en) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Diagnostic agents for amyloid beta imaging
US20130211108A1 (en) 2010-06-18 2013-08-15 Mylan Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
EP2614055A2 (en) * 2010-09-10 2013-07-17 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
GB201019043D0 (en) 2010-11-10 2010-12-22 Protea Biopharma N V Use of 2',5'-oligoadenylate derivative compounds
WO2012085625A1 (en) 2010-12-21 2012-06-28 Lupin Limited Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
WO2012107937A2 (en) * 2011-02-10 2012-08-16 Mylan Laboratories Ltd Crystalline fosamprenavir calcium and process for the preparation thereof"
EP3656860B1 (en) 2011-06-21 2022-04-20 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
US20140235693A1 (en) 2011-06-23 2014-08-21 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
WO2013009844A2 (en) * 2011-07-11 2013-01-17 Purdue Research Foundation C-3 substituted bicyclooctane based hiv protease inhibitors
WO2013011485A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of sulfonamides useful as retroviral protease inhibitors
IN2012DE00082A (sl) 2012-01-10 2015-05-01 Council Scient Ind Res
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
EP2700396A3 (en) 2012-06-20 2015-04-29 Sylphar Nv Strip for the delivery of oral care compositions
WO2014059034A2 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
KR102186030B1 (ko) 2012-10-29 2020-12-03 시플라 리미티드 항 바이러스성 포스포네이트 유사체 및 이의 제조를 위한 방법
NZ709013A (en) 2012-12-05 2020-01-31 Alnylam Pharmaceuticals Inc Pcsk9 irna compositions and methods of use thereof
CN114015692B (zh) 2013-03-14 2024-12-31 阿尔尼拉姆医药品有限公司 补体组分C5 iRNA组合物及其使用方法
MX379208B (es) 2013-05-22 2025-03-10 Alnylam Pharmaceuticals Inc Composiciones de arni de serpina1 y sus metodos de uso.
EP3828276A1 (en) 2013-05-22 2021-06-02 Alnylam Pharmaceuticals, Inc. Tmprss6 irna compositions and methods of use thereof
KR20240170595A (ko) 2013-12-12 2024-12-03 알닐람 파마슈티칼스 인코포레이티드 보체 성분 ｉＲＮＡ 조성물 및 이의 이용 방법
KR102592370B1 (ko) 2014-02-11 2023-10-25 알닐람 파마슈티칼스 인코포레이티드 케토헥소키나제(ＫＨＫ) ｉＲＮＡ 조성물 및 그의 사용 방법
WO2015175510A1 (en) 2014-05-12 2015-11-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a serpinc1-associated disorder
CN112852809A (zh) 2014-05-22 2021-05-28 阿尔尼拉姆医药品有限公司 血管紧张素原(AGT)iRNA组合物及其使用方法
WO2016003450A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Pkc-epsilon inhibitors
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
TW202412806A (zh) 2014-07-11 2024-04-01 美商基利科學股份有限公司 用於治療HIV之toll樣受體調節劑
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
WO2016061487A1 (en) 2014-10-17 2016-04-21 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
US9738664B2 (en) 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
EP3212794B1 (en) 2014-10-30 2021-04-07 Genzyme Corporation Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
WO2016081444A1 (en) 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
WO2016083490A1 (en) 2014-11-27 2016-06-02 Remynd Nv Compounds for the treatment of amyloid-associated diseases
AU2016219263B2 (en) 2015-02-13 2022-12-01 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
KR102749152B1 (ko) 2015-04-13 2025-01-06 알닐람 파마슈티칼스 인코포레이티드 안지오포이에틴-유사 3(angptl3) irna 조성물 및 이의 이용 방법
KR20180006389A (ko) 2015-04-28 2018-01-17 뉴사우쓰 이노베이션스 피티와이 리미티드 화학요법 및 방사선요법 유도 인지 장애, 신경병증 및 비활동성을 치료하기 위한 nad+ 표적화
AU2016257996A1 (en) 2015-05-06 2017-10-26 Alnylam Pharmaceuticals, Inc. Factor XII (Hageman Factor) (F12), Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA compositions and methods of use thereof
EP3310918B1 (en) 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
EP3350328A1 (en) 2015-09-14 2018-07-25 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
US20180263985A1 (en) 2015-09-15 2018-09-20 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
KR20180095843A (ko) 2015-12-07 2018-08-28 젠자임 코포레이션 Serpinc1-연관 장애의 치료를 위한 방법 및 조성물
EP3387129A1 (en) 2015-12-10 2018-10-17 Alnylam Pharmaceuticals, Inc. STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP2019518028A (ja) 2016-06-10 2019-06-27 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 補体成分Ｃ５ｉＲＮＡ組成物及び発作性夜間血色素尿症（ＰＮＨ）を処置するためのその使用方法
TWI788312B (zh) 2016-11-23 2023-01-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
JP7058656B2 (ja) 2016-12-16 2022-04-22 アルナイラム ファーマシューティカルズ， インコーポレイテッド トランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物を用いてＴＴＲ関連疾患を治療または予防するための方法
US12178805B2 (en) 2017-05-11 2024-12-31 Remynd N.V. Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders
EA201992397A1 (ru) 2017-05-11 2020-03-16 Реминд Н.В. Соединения для лечения эпилепсии, нейродегенеративных нарушений и других нарушений цнс
BR112020000400A2 (pt) 2017-07-10 2020-07-14 Genzyme Corporation métodos e composições para o tratamento de um caso de hemorragia em um indivíduo com hemofilia
EP3654980A1 (en) 2017-07-21 2020-05-27 VIIV Healthcare Company Regimens for treating hib infections and aids
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
EP3704252A1 (en) 2017-11-01 2020-09-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
EA202190528A1 (ru) 2018-08-13 2021-04-23 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ АГЕНТОВ дцРНК ВИРУСА ГЕПАТИТА B (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AU2020209186A1 (en) 2019-01-16 2021-09-09 Genzyme Corporation Serpinc1 iRNA compositions and methods of use thereof
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
BR112022016733A2 (pt) 2020-02-24 2022-10-11 Univ Leuven Kath Compostos antivirais de pirrolpiridina e imidazopiridina
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
WO2022136486A1 (en) 2020-12-22 2022-06-30 Luxembourg Institute Of Health (Lih) Conolidine analogues as selective ackr3 modulators for the treatment of cancer and cardiovascular diseases
WO2022184898A1 (en) 2021-03-04 2022-09-09 Universiteit Antwerpen Quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one inhibitors of erbb4 (her4) for use in the treatment of cancer
CA3217589A1 (en) 2021-05-31 2022-12-08 Frederik Giesel Improved prostate-specific membrane antigen targeting radiopharmaceuticals and uses thereof
EP4387629A1 (en) 2021-08-18 2024-06-26 Katholieke Universiteit Leuven KU Leuven Research & Development 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues
EP4405357A1 (en) 2021-09-23 2024-07-31 Katholieke Universiteit Leuven KU Leuven Research & Development Ribonucleoside analogues against -sars-cov-2
WO2023241799A1 (en) 2022-06-15 2023-12-21 Université Libre de Bruxelles Flavanols for use in the treatment of retroviral infections
WO2024062043A1 (en) 2022-09-21 2024-03-28 Universiteit Antwerpen Substituted phenothiazines as ferroptosis inhibitors
WO2024175804A1 (en) 2023-02-24 2024-08-29 Katholieke Universiteit Leuven Nuclear transport modulators
WO2025104221A1 (en) 2023-11-15 2025-05-22 Université Libre de Bruxelles Uses of protein tyrosine phosphatase receptor kappa inhibitors
WO2025157901A1 (en) 2024-01-26 2025-07-31 Aneurotech Bv Piperidine carboxamide fatty acid prodrugs

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743722A (en) 1971-07-14 1973-07-03 Abbott Lab Anti-coagulant isolation
FR2459235A1 (fr) 1979-06-14 1981-01-09 Sanofi Sa Nouveaux derives de sulfonyl-aniline, leur procede de preparation et leur application therapeutique
JPS5946252A (ja) 1982-09-09 1984-03-15 Dainippon Ink & Chem Inc 含フツ素アミノカルボキシレ−トおよびその製法
JPS5948449A (ja) 1982-09-13 1984-03-19 Dainippon Ink & Chem Inc 直鎖状含フツ素アニオン化合物およびその製造方法
JPS6171830A (ja) 1984-09-17 1986-04-12 Dainippon Ink & Chem Inc 界面活性剤組成物
US4616088A (en) 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US4629724A (en) 1984-12-03 1986-12-16 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitors
DE3635907A1 (de) 1986-10-22 1988-04-28 Merck Patent Gmbh Hydroxy-aminosaeurederivate
NL8800100A (nl) 1987-01-21 1988-08-16 Sandoz Ag Nieuwe peptidederivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
CA1340588C (en) 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
IL91780A (en) 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
WO1990007330A1 (en) 1989-01-06 1990-07-12 The Regents Of The University Of California Selection method for specific useful pharmaceutical compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5151438A (en) 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
IE902295A1 (en) 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
HU9203505D0 (en) 1990-06-01 1993-01-28 Du Pont Merck Pharma 1,4-diamino-2,3-dihydroxi-butane compounds
TW225540B (sl) 1990-06-28 1994-06-21 Shionogi & Co
EP0735019B1 (en) 1990-11-19 2000-09-20 Monsanto Company Retroviral protease inhibitors
ES2059296T3 (es) 1990-11-19 1996-07-16 Monsanto Co Inhibidores de proteasas retrovirales.
ATE296625T1 (de) 1990-11-19 2005-06-15 Monsanto Co Retrovirusprotease inhibitoren
HU9301446D0 (en) 1990-11-19 1993-11-29 Monsanto Co Inhibitors or fetrovirus protease
IE913840A1 (en) 1990-11-20 1992-05-20 Abbott Lab Retroviral protease inhibiting compounds
NZ244986A (en) 1991-11-08 1995-10-26 Merck & Co Inc Hiv protease inhibitor and pharmaceutical compositions
DE69304051T2 (de) 1992-05-20 1997-01-23 Monsanto Co Verfahren zur herstellung von intermediaten in der synthese von retroviralen protease inhibitoren
ATE199545T1 (de) 1992-05-21 2001-03-15 Monsanto Co Inhibitoren retroviraler proteasen
WO1994004493A1 (en) 1992-08-25 1994-03-03 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
DK0656886T3 (da) 1992-08-25 1998-02-02 Searle & Co N-(Alkanoylamino-2-hydroxypropyl)-sulfonamider til anvendelse som inhibitorer af retrovirale proteaser
ES2123065T3 (es) 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
CA2120956A1 (en) * 1992-09-03 1994-03-17 Franz Esser New amino acid derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
TW372972B (en) 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
ES2118364T3 (es) 1992-10-30 1998-09-16 Searle & Co Derivados de acido hidroxietilamino-sulfamico utiles como inhibidores de proteasas retroviricas.
ATE183499T1 (de) 1992-10-30 1999-09-15 Searle & Co Sulfonylalkanoylaminohydroxyethylaminosulfamins uren verwendbar als inhibitoren retroviraler proteasen
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
WO1994018192A1 (en) 1993-02-12 1994-08-18 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
JP3419539B2 (ja) 1993-02-17 2003-06-23 中外製薬株式会社 インドリン−２−オン誘導体
EP0715618B1 (en) 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
IL110898A0 (en) 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
IL111584A0 (en) 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
US5527829A (en) 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DE19506742A1 (de) 1995-02-27 1996-08-29 Bayer Ag Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen
US5691372A (en) 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5750493A (en) 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US5646180A (en) 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
EP1042280A2 (en) * 1997-12-24 2000-10-11 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
CO5261510A1 (es) * 1999-02-12 2003-03-31 Vertex Pharma Inhibidores de aspartil proteasa

Also Published As

Publication number Publication date
CN100503589C (zh) 2009-06-24
US20050148548A1 (en) 2005-07-07
SK287123B6 (sk) 2009-12-07
US20100124543A1 (en) 2010-05-20
US6838474B2 (en) 2005-01-04
RS52483B (en) 2013-02-28
ES2299193T3 (es) 2008-05-16
IS5546A (is) 2000-06-22
LU91426I9 (sl) 2018-12-28
DE122008000021I2 (de) 2010-02-04
EA200000703A1 (ru) 2000-12-25
EP0933372B1 (en) 2007-12-26
NO326265B1 (no) 2008-10-27
CN1284071A (zh) 2001-02-14
MY131525A (en) 2007-08-30
DK0933372T3 (da) 2008-04-28
HUP0101831A2 (hu) 2002-04-29
NZ505776A (en) 2003-06-30
YU39800A (sh) 2004-03-12
US7592368B2 (en) 2009-09-22
EP1944300A2 (en) 2008-07-16
IL136941A0 (en) 2001-06-14
EE04466B1 (et) 2005-04-15
SK9662000A3 (en) 2001-02-12
KR100520737B1 (ko) 2005-10-12
LU91426I2 (fr) 2008-06-02
TW486474B (en) 2002-05-11
AP2000001850A0 (en) 2000-06-30
CA2231700A1 (en) 1999-06-24
PT933372E (pt) 2008-03-31
JP2009102400A (ja) 2009-05-14
ID24962A (id) 2000-08-31
US6436989B1 (en) 2002-08-20
PE20000048A1 (es) 2000-02-08
ME00561B (me) 2011-10-10
CZ20002363A3 (cs) 2000-11-15
JP3736964B2 (ja) 2006-01-18
BG104631A (en) 2001-02-28
AU6546698A (en) 1999-07-19
JP4282639B2 (ja) 2009-06-24
AP1172A (en) 2003-06-30
KR20010033600A (ko) 2001-04-25
DE69838903T2 (de) 2008-09-18
PL342113A1 (en) 2001-05-21
ZA9811830B (en) 2000-06-23
IL136941A (en) 2006-06-11
EP0933372A1 (en) 1999-08-04
HUS1400042I1 (hu) 2017-06-28
JPH11209337A (ja) 1999-08-03
OA11468A (en) 2004-05-05
AR017965A1 (es) 2001-10-24
CA2231700C (en) 2005-08-09
NL300339I2 (nl) 2009-11-02
CN101565412A (zh) 2009-10-28
HK1021737A1 (en) 2000-06-30
JP2005350478A (ja) 2005-12-22
WO1999033815A1 (en) 1999-07-08
EP1944300A3 (en) 2008-11-05
US20030207871A1 (en) 2003-11-06
DE69838903D1 (de) 2008-02-07
NO2009008I1 (sl) 2009-05-04
HUP0101831A3 (en) 2002-08-28
EE200000385A (et) 2001-12-17
DE122008000021I1 (de) 2008-08-14
BG64869B1 (bg) 2006-07-31
CO4990992A1 (es) 2000-12-26
NO2009008I2 (sl) 2010-09-27
HU229596B1 (en) 2014-02-28
US6559137B1 (en) 2003-05-06
FR08C0015I1 (sl) 2008-05-30
IS2817B (is) 2012-11-15
FR08C0015I2 (fr) 2009-10-30
AU755087B2 (en) 2002-12-05
ATE382042T1 (de) 2008-01-15
UA72733C2 (en) 2005-04-15
NO20003304D0 (no) 2000-06-23
NO20003304L (no) 2000-08-21
MEP82008A (en) 2011-12-20
BR9814480A (pt) 2001-09-25
CZ301653B6 (cs) 2010-05-12
EA003509B1 (ru) 2003-06-26
NL300339I1 (nl) 2008-06-02
TR200002615T2 (tr) 2001-01-22
PL202845B1 (pl) 2009-07-31

Similar Documents

Publication Publication Date Title
HUS1400042I1 (hu) Szulfonamid-származékok mint aszpartil-proteáz inhibitorok prodrugjai
AU2012199A (en) Prodrugs of aspartyl protease inhibitors
EE200000386A (et) Aspartüülproteaasi inhibiitorite eelravimid
AU2010299A (en) Prodrugs os aspartyl protease inhibitors
AP2000002023A0 (en) Sulfonamide inhibitors of aspartyl protease
EG23936A (en) Bisulfate salt of h i v protease inhibitor
AU8875398A (en) 1-amino-7-isoquinoline derivatives as serine protease inhibitors
AP9701119A0 (en) THF-containing sulfonamide inhibitors of aspartyl protease
HUP0300385A3 (en) Inhibitors of aspartyl protease
HUP9902409A3 (en) Inhibitors of cysteine protease
AU7127298A (en) Serine protease inhibitors
ZA983629B (en) Serine protease inhibitors
ZA962891B (en) Oxgenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
IL142398A0 (en) Serine protease inhibitor
EP0923535A4 (en) CYSTEINE PROTEASE INHIBITORS
PL337725A1 (en) Inhibitors of proteases
PL328665A1 (en) Inhibitors of serinic protease
AP9700961A0 (en) Aspartyl protease inhibitors
AU3868499A (en) Hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases
ZA97613B (en) Aspartyl protease inhibitors
AU7133898A (en) Nanosized aspartyl protease inhibitors
HK1032225A (en) Prodrugs of aspartyl protease inhibitors
SI0846110T1 (sl) THF-vsebujoči sulfonamidni inhibitorji aspartil proteaze
SI0763017T1 (sl) Derivati N-(3-amino-2hidroksibutil)sulfonamida kot inhibitorji HIV proteaze
SI0936912T1 (sl) Inhibitorji cistein-proteaze